de Boer C J, van Krieken J H, Kluin-Nelemans H C, Kluin P M, Schuuring E
Department of Pathology, University of Leiden, Academic Hospital Leiden, The Netherlands.
Oncogene. 1995 May 4;10(9):1833-40.
In mantle cell lymphoma (MCL) a recurrent chromosomal rearrangement, t(11;14)(q13;q32), has been described. Most breakpoints have been detected within the 120 kb BCL-1 region, upstream of the cyclin D1 gene. To evaluate the association between BCL-1 rearrangement and expression of cyclin D1 in lymphoproliferative disorders, we analysed a series of 24 MCL, 56 other B-cell non-Hodgkin's lymphomas (NHL), 28 chronic B-cell leukemias, 18 hematopoietic cell lines and 10 normal lymphoid tissues at the RNA level. Hematopoietic cell lines with a known 11q13 translocation showed high expression of the 4.5 kb cyclin D1 transcript. Three B-cell lines without known 11q13 breakpoint showed low expression. We detected high expression in all (11/11) MCL with and in 11 out of 13 cases of MCL without detectable t(11;14) rearrangement. In three cases with a rearrangement at the 3' end of cyclin D1, two showed overexpression of the 1.5 kb transcript and one expression of an aberrant (3.0 kb) transcript. In other lymphoproliferative disorders, only 5/15 hairy cell leukemias, all without detectable t(11;14), and 5/8 B-cell leukemias suspected to be MCL in leukemic phase showed expression levels comparable to MCL, whereas no or only low expression were observed in 56 cases of other NHL, seven chronic B-cell leukemias and all (10/10) normal lymphoid tissues. Cell sorting experiments on fresh tonsils showed that this low expression was present in normal B-cells and not in T-cells. In contrast to other studies, our data indicate that cyclin D1 is expressed in many lymphoproliferative disorders and normal tissues, albeit at low levels. High levels of expression of cyclin D1 however is restricted to MCL and some hairy cell leukemias. We therefore propose that overexpression of cyclin D1 is a reliable marker for the classification of MCL.
在套细胞淋巴瘤(MCL)中,已发现一种复发性染色体重排,即t(11;14)(q13;q32)。大多数断点已在细胞周期蛋白D1基因上游120 kb的BCL-1区域内检测到。为了评估BCL-1重排与细胞周期蛋白D1在淋巴增殖性疾病中的表达之间的关联,我们在RNA水平上分析了一系列24例MCL、56例其他B细胞非霍奇金淋巴瘤(NHL)、28例慢性B细胞白血病、18种造血细胞系和10例正常淋巴组织。已知有11q13易位的造血细胞系显示出4.5 kb细胞周期蛋白D1转录本的高表达。3个无已知11q13断点的B细胞系显示低表达。我们在所有(11/11)有t(11;14)重排的MCL以及13例无 detectable t(11;14)重排的MCL中的11例中检测到高表达。在3例细胞周期蛋白D1 3'端有重排的病例中,2例显示1.5 kb转录本的过表达,1例显示异常(3.0 kb)转录本的表达。在其他淋巴增殖性疾病中,仅5/15例毛细胞白血病(均无detectable t(11;14))以及5/8例疑似处于白血病期的MCL的B细胞白血病显示出与MCL相当的表达水平,而在56例其他NHL、7例慢性B细胞白血病和所有(10/10)正常淋巴组织中未观察到表达或仅观察到低表达。对新鲜扁桃体进行的细胞分选实验表明,这种低表达存在于正常B细胞中,而不存在于T细胞中。与其他研究不同,我们的数据表明细胞周期蛋白D1在许多淋巴增殖性疾病和正常组织中均有表达,尽管水平较低。然而,细胞周期蛋白D1的高水平表达仅限于MCL和一些毛细胞白血病。因此,我们提出细胞周期蛋白D1的过表达是MCL分类的可靠标志物。